Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics reports developments for a clinical-stage biopharmaceutical business focused on tumor-activated immunotherapies and immune-engaging drug candidates. The company applies its TRACTr, TRACIr and ARM platforms to programs in oncology and autoimmune disease, including PSMA-directed prostate cancer candidates and a CD19-targeted ARM candidate.
Recurring news themes include clinical progress for JANX007, JANX014 and JANX011, portfolio decisions such as the discontinued JANX008 program, financial results and business highlights, collaboration milestones with Bristol Myers Squibb, and leadership or governance updates tied to the company’s clinical development organization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.